Imprint Labs, LLC

Imprint Labs, LLC, based in the US, develops innovative immunology tools that analyze immune memory signatures to address chronic disease challenges. Founded in 2023 and headquartered in New York, US, Imprint Labs, LLC specializes in immunological research tools. The company has secured USD 15. 00 mn in funding through a single deal, with the most recent funding round occurring on May 21, 2025.

The founder's background details are not provided. IMPRINT specializes in developing advanced immunology tools designed to read and analyze immune memory signatures. Their core offerings focus on reconstructing immune histories from memory B cells and T cells, addressing significant challenges in identifying hidden causes of chronic diseases such as autoimmune disorders, long-COVID, psychiatric conditions, and dementia. These tools serve a diverse clientele, including researchers, healthcare providers, and pharmaceutical companies, enabling them to gain insights into the underlying mechanisms of chronic diseases and explore potential treatment avenues.

IMPRINT’s products are actively marketed within the United States and Europe, targeting regions with a robust biomedical research and healthcare infrastructure. The company’s commitment to scalable and cost-efficient solutions emphasizes accessibility for professionals engaged in immunological research and clinical diagnostics. IMPRINT structures its revenue through a combination of partnerships, subscriptions, and direct sales of its immunological research tools. Typically, clients engage in long-term partnerships that allow for continuous access to the company's products, fostering an environment for ongoing research and development.

This model supports the sale of services that can be tailored to specific research needs, with a focus on collaboration with academic institutions, biotech firms, and healthcare facilities. The revenue generated is closely tied to the flagship tools that IMPRINT offers, which are instrumental in decoding complex immune responses and contributing to the advancement of therapeutic strategies. By embedding their products within existing biomedical workflows, IMPRINT ensures a steady stream of revenue while enhancing the capabilities of their clients in the field of immunology. In May 2025, Imprint Labs, LLC raised USD 15.

00 mn in venture funding to support future growth initiatives. The company plans to develop new products aimed at enhancing the accuracy and efficiency of immunological research tools, with releases expected in late 2025. Additionally, Imprint Labs seeks to expand its market presence into Asia and South America by 2026, targeting regions that are increasingly investing in healthcare innovation.